Coordinatore | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
Nazionalità Coordinatore | Germany [DE] |
Sito del progetto | http://www.eva-copd.eu/ |
Totale costo | 3˙952˙828 € |
EC contributo | 2˙984˙025 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-A |
Funding Scheme | CP-FP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-10-01 - 2012-03-31 |
# | ||||
---|---|---|---|---|
1 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | coordinator | 0.00 |
2 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 0.00 |
3 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
4 |
EUROPEAN RESPIRATORY SOCIETY
Organization address
address: Avenue Sainte Luce 4 contact info |
CH (LAUSANNE) | participant | 0.00 |
5 |
FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA
Organization address
address: Baldiri i Reixac, 10-12 contact info |
ES (BARCELONA) | participant | 0.00 |
6 |
INSTYTUT GRUZLICY I CHOROB PLUC
Organization address
address: UL. PLOCKA 26 contact info |
PL (WARSZAWA) | participant | 0.00 |
7 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 0.00 |
8 |
ORSZAGOS KORANYI TBE ES PULMONOLOGIAI INTEZET
Organization address
address: UTCA PIHENO 1 contact info |
HU (BUDAPEST) | participant | 0.00 |
9 |
P & M VENGE AB
Organization address
address: SKOLGATAN 23 contact info |
SE (UPPSALA) | participant | 0.00 |
10 |
PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
DE (MARBURG) | participant | 0.00 |
11 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 0.00 |
12 |
UNIVERSITA DEGLI STUDI DI FERRARA
Organization address
address: SAVONAROLA 9 contact info |
IT (FERRARA) | participant | 0.00 |
13 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 0.00 |
14 |
UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NATIONAL HEALTH SERVICE TRUST
Organization address
address: CLIFFORD BRIDGE ROAD contact info |
UK (COVENTRY) | participant | 0.00 |
15 |
UNIVERSITY OF LEICESTER
Organization address
address: University Road contact info |
UK (LEICESTER) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'COPD is characterized by emphysema (destruction of the lung alveoli) and airway disease (inflammation and thickening of the bronchial wall) both of which lead to airway obstruction. These two features co-exist in most patients but some patients present with only emphysema (E) or only airway disease (A). The aim of the project is to identify markers specific to E and A of COPD. Our hypothesis is that the mechanisms leading to these pathologies are distinct with respect to the type of inflammatory response and in terms of genetic predisposition. The differential pathogenesis for emphysema (E) and inflammatory airway disease (A) entails that in the two forms of COPD are linked to different markers at the DNA, RNA and protein level. Using computer tomography (CT) scans for selection of patients with emphysema only and airway disease only, we will obtain material from lung (leukocytes, bronchial cells) and blood (leukocytes), and will analyse elements of gene expression (SNP array, transcriptome). Data analysis will be done for E versus A (EvA) and versus a control cohort leading to identification of markers linked specifically to either E or A. These markers will be elements involved in a differential pathogenesis for the different disease processes in COPD. They can be used for diagnostic approaches and as therapeutic targets.'
Chronic obstructive pulmonary disease ranks high on the global mortality list. It is characterised by emphysema and airway disease, both of which lead to airway obstruction.
Although most chronic obstructive pulmonary disease (COPD) patients have both emphysema and airway disease, in some cases only one of the features is present. The 'Markers for emphysema versus airway disease in COPD' (EVA) project aims to identify markers linked specifically to emphysema and airway disease at the DNA, RNA and protein levels. The EU-funded project is working on the hypothesis that the processes leading to these pathologies can be differentiated with regard to inflammatory response and genetic predisposition.
Participating clinical centres have to date recruited some 180 cases and 170 healthy controls. Computer tomography (CT) scans are being used to select patients with either emphysema or airway disease. Image analysis will further define emphysema based on density of the lung tissue, and airway disease based on thickness of the airway wall. By plotting airway wall area against lung density, patients can be identified as having emphysema only or airway disease only.
Material obtained from lungs and blood will be analysed for elements of gene expression. However, crucial analysis will be performed in a single batch at the end of the study, when all samples have been collected. At that point, DNA, RNA and protein data will be available for cases as well as controls. This will help EVA produce the results required to identify markers specifically associated with emphysema and airway disease sub-phenotypes.
As elements of the differential pathogenesis for the different disease processes in COPD, these markers will be extremely useful for diagnosing the sub-phenotypes. Such markers will also provide a basis for exploring targets for new therapeutic approaches to COPD. This will also afford greater opportunities to better manage the disease.
Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD)
Read MoreExploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention
Read More"Large-scale, high-throughput automated systems for phenotyping mouse models of human disease"
Read More